-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Roivant Sciences, Raises Price Target to $26

Benzinga·11/11/2025 19:59:42
Listen to the news
Citigroup analyst Samantha Semenkow maintains Roivant Sciences (NASDAQ:ROIV) with a Buy and raises the price target from $25 to $26.